PharmiNews

The Directory of Pharma Companies and News

Celgene

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Category: Pharmaco
Category: Pharmaco

Celgene News

DateNews
2016-04-01Celgene Corporation to Announce First Quarter 2016 Results on April 28, 2016
2016-03-18Oral Ozanimod Showed Histologic Improvements in Patients with Ulcerative Colitis in the Phase 2 TOUCHSTONE Trial
2016-03-07Oral OTEZLA® (Apremilast) Long-Term Safety Data Presented at American Academy of Dermatology Congress
2016-03-07Celgene Notified of ANDA Filing for ABRAXANE®
2016-03-04Oral OTEZLA® (apremilast) Data from Open-Label Phase of ESTEEM and LIBERATE™ Trials to Be Presented at American Academy ...
2016-02-18Oral Ozanimod 72-Week Phase 2 Results From RADIANCE Trial in Relapsing Multiple Sclerosis Presented At ACTRIMS
2016-02-11Celgene Corporation Elects Mark Alles and Jacqualyn Fouse PhD to its Board of Directors
2016-02-01Celgene Corporation to Webcast at Upcoming Investor Conferences
2016-01-28Celgene Reports Fourth Quarter and Full Year 2015 Operating and Financial Results
2016-01-22Be Counted! Campaign Brings Together the Psoriatic Arthritis Community to Increase Understanding of This Chronic, Autoim...
2016-01-22Data Presented at ASCO GI Highlight the Feasibility of Second-Line Treatment in Patients with Metastatic Pancreatic Canc...
2016-01-22Investigational Combinations Using an ABRAXANE and Gemcitabine Foundation Lead ASCO GI Pancreatic Cancer Research
2016-01-11Organizational Changes Strengthen Leadership Team and Position Celgene for Long-Term Growth
2016-01-11Celgene Corporation Announces 2016 Financial Outlook and Preliminary 2015 Results
2016-01-05Celgene Corporation to Announce Fourth Quarter and Full-Year 2015 Results on January 28, 2016
2016-01-04Celgene Corporation to Present at the 34th Annual J.P. Morgan Healthcare Conference
2015-12-22Celgene Settles REVLIMID® Patent Litigation
2015-12-21Oral REVLIMID® Plus Dexamethasone Granted Approval for Treatment of Patients with Newly Diagnosed Multiple Myeloma in Ja...
2015-12-09Abstracts at San Antonio Breast Cancer Symposium Highlight ABRAXANE® as a Potential Backbone Therapy in Neoadjuvant and ...
2015-12-07Celgene in Collaboration with Astrazeneca Announce Initiation of Fusion Clinical Development Program in Immuno-Oncology
2015-12-06IMiD® Combination Therapies Form Backbone of Multiple Myeloma Research at ASH
2015-12-05Study of Bortezomib Added to Revlimid® and Dexamethasone Backbone Therapy Presented at ASH
2015-11-05Celgene Reports Third Quarter 2015 Operating and Financial Results
2015-10-30Celgene's VIDAZA® (Azacitidine For Injection) Approved By The European Commission As New Treatment For Elderly Patients ...
2015-10-27Celgene Corporation to Webcast at Upcoming Investor Conference and Medical Congress
2015-10-26Phase 2 Maintenance Data from Oral Ozanimod TOUCHSTONE Study in Ulcerative Colitis Presented at UEG Week
2015-10-19Phase 2 Maintenance Data from Oral Ozanimod TOUCHSTONE Study in Ulcerative Colitis Presented at ACG Plenary Session
2015-10-16Celgene Corporation Elects Julia A. Haller, M.D., to Its Board of Directors
2015-10-12One Year Data from Phase III Study Evaluating Oral OTEZLA® (apremilast) or Injectable etanercept versus Placebo in Patie...
2015-10-09Celgene Announces New Data for OTEZLA® (Apremilast) Will Be Presented at European Academy of Dermatology and Venereology...
2015-10-01Celgene Corporation to Announce Third Quarter 2015 Results on November 5, 2015
2015-09-25Celgene's VIDAZA® (Azacitidine for Injection) Receives Positive CHMP Opinion as New Treatment for Elderly Patients with ...
2015-08-27Celgene Completes Acquisition of Receptos, Advancing Leadership in Immune-Inflammatory Diseases
2015-08-26Celgene Corporation to Webcast Upcoming Investor Conferences in September
2015-08-25Celgene Announces Expiration of Cash Tender Offer for Shares of Receptos, Inc.
2015-08-11Celgene Receives Antitrust Clearance for Receptos Acquisition
2015-08-04Celgene Prices $8 Billion of Senior Unsecured Notes
2015-08-03Celgene Announces Offering of Senior Unsecured Notes
2015-07-28Celgene Corporation Commences Tender Offer for Receptos, Inc.
2015-07-23Celgene Reports Second Quarter 2015 Operating and Financial Results
2015-07-14Celgene to Acquire Receptos, Advancing Leadership in Immune-Inflammatory Diseases
2015-07-06Celgene Corporation to Announce Second Quarter 2015 Results on July 23, 2015
2015-06-29Celgene and Juno Announce Ten-Year Collaboration to Advance Potentially Groundbreaking Immunotherapies for Patients with...
2015-06-17Celgene Announces Additional $4 Billion Share Repurchase Authorization
2015-06-13Results from Analyses of Revlimid® MCL-002 (SPRINT) Study Presented at EHA
2015-06-12Updated Results from MM-020/IFM 07-01 (First) Study of REVLIMID® Presented at European Hematology Annual Congress
2015-06-09Oral Presentation Evaluating Pooled Data on OTEZLA® (apremilast) for Long-Term Improvements in Enthesitis and Dactylitis...
2015-06-03Celgene Announces New Data to be Presented at European League Against Rheumatism Annual Congress
2015-05-28Celgene Corporation to Webcast at Upcoming Investor Conferences in June
2015-05-19Analysis of Phase II Data for Celgene's Investigational Oral GED-0301 in Patients with Active Crohn's Disease Presented ...
2015-05-13Celgene Announces Presentations of Investigational Studies in Solid Tumor and Blood Cancers at ASCO 2015
2015-05-01Analysis of REVLIMID® (Lenalidomide) in Patients with Non-Del-5Q MDS Demonstrated Improved Health Related Quality of Lif...
2015-04-30Celgene Reports First Quarter 2015 Operating and Financial Results
2015-04-27Celgene to Acquire Quanticel Pharmaceuticals
2015-04-24Celgene Corporation Enters into Strategic Immuno-Oncology Collaboration with AstraZeneca to Develop PD-L1 Inhibitor Prog...
2015-04-23Celgene Corporation to Webcast at Upcoming Investor Conferences and Medical Meetings in May
2015-04-23POMALYST® (pomalidomide) Label Update Including Progression-Free and Overall Survival Benefits Approved by U.S. FDA
2015-04-15Celgene Corporation Elects Mr. Michael W. Bonney to Its Board of Directors
2015-04-15Phase II Data for Apremilast in Behçet's Disease Published in The New England Journal of Medicine
2015-04-01Celgene Corporation to Announce First Quarter 2015 Results on April 30, 2015
2015-04-01Celgene Corporation Announces the Appointment of Gerald F. Masoudi as Executive Vice President, General Counsel and Corp...
2015-03-20Oral OTEZLA® (apremilast) Long-Term Safety and Efficacy Data in Patients with Moderate to Severe Plaque Psoriasis Presen...
2015-03-20Positive Results from Phase III Study Evaluating Oral OTEZLA® (Apremilast) or Injectable Etanercept versus Placebo in Pa...
2015-03-18Phase II Data for Celgene's Investigational Oral GED-0301 for Patients with Active Crohn's Disease Published in New Engl...
2015-03-02ABRAXANE® Approved by European Commission for First-Line Treatment of Patients with Non-Small Cell Lung Cancer
2015-02-25Celgene Encourages Psoriatic Arthritis Patients to “pSAY YES!” a Different Approach to Disease Management (PDF)
2015-02-20REVLIMID® (Lenalidomide) Approved by the European Commission for the Treatment of Adult Patients with Previously Untreat...
Brought to you by PharmiWeb.com - Latest Jobs in Pharma
Brought to you by www.pharmiweb.com - Latest Jobs in Pharma.